Neurocrine Biosciences (NBIX) provided an update on its business performance, including preliminary net product sales results for 2018, and key clinical development programs for 2019. Kevin Gorman, Chief Executive Officer of Neurocrine, will discuss these updates as part of a webcast presentation at the 37th Annual JPMorgan Healthcare Conference in San Francisco on Monday. Based on preliminary unaudited financial information, the Company expects net product sales for the three months and full-year ended December 31, 2018 to be approximately $130M and $409M, respectively, compared to $64.5M and $116.6M for the same periods in 2017. Regarding 2019 milestones, the company expects “Talk About TD” disease state awareness campaign; execution of post-marketing clinical studies, including RE-KINECT; presentations at key scientific annual meetings; elagolix in collaboration with AbbVie (ABBV); continued launch of ORILISSA to treat endometriosis by AbbVie; Elagolix for uterine fibroids: planned 2019 New Drug Application submission Opicapone for Parkinson’s Disease; preparation for 2020 opicapone commercial launch; Phase IIa data for CAH – adults – in Q1 2019; Phase IIa initiation for CAH – pediatric – in Q2/Q3 2019; Pivotal study initiation for CAH – adults – in 2H 2019, pending Food and Drug Administration discussion in Q2; Investigational New Drug submission and initiation of a Phase I trial for a new, internally discovered program.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.